# Annexon

**Canonical:** https://apis.io/providers/annexon/  
**Website:** https://annexonbio.com  
**APIs profiled:** 0

Annexon Biosciences develops therapies that target the classical complement pathway by inhibiting C1q. The company focuses on treating autoimmune, neurodegenerative, and ophthalmic diseases, and has advanced a first‑in‑class C1q‑blocking antibody, ANX005, into a pivotal Phase 3 trial for Guillain‑Barré syndrome. Its pipeline includes early complement inhibitors for conditions of the body, brain, and eye.

## Kin Score — 7.9 / 100 (minimal)

Scored 2026-10-31 under rubric 0.25.0.

| Facet | Score |
|---|---|
| Discoverability | 39.3 |
| Contract Quality | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Access Clarity | 21.1 |

Regulatory layer — **Horizontal (data, software, accessibility, platform)**: 13.7 (matched via fallback).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |
| Pagination Ratio | na |
| Operation Distinctiveness | na |

## Security (1)

- **Annexon Domain Security** — TLSv1.3 · DMARC

## Tags

Autoimmune diseases, Neurodegenerative diseases, Ophthalmic diseases

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/annexon/). Scores are computed from the provider's own public artifacts under a published rubric.